Substitution-for-Morphine (SDS) Test. Male and female rhesus monkeys (M. mulatta) weighing 2.5-7.5 kg were used, and they received 3 mg/kg, s.c., of morphine . SO 4 every 6 hr. All the animals had received morphine for at least 3 months and were maximally dependent on morphine (Seevers and Deneau 1963) . A m inimal 2-week recuperation period was allowed between tests. At least 3 monkeys/dose were used. The assay coworkers, 1977 and was initiated by a subcutaneous injection of the test drug or control substances (morphine and vehicle) into animals in a group that had not received morphine for 14-15 hr and showed definite signs of withdrawal. Each animal was randomly chosen to receive one of the following treatments: a) a dose of the compound under investigation; b) morphine control, 3.0 mg/kg; and c) vehicle control, 1 ml/kg. The animals were scored for suppression of withdrawal signs during a 2.5-hr observation period. The observer was "blind" regarding the choice of treatments. At the end of the study, the data were grouped according to dose and drug. The mean cumulative score ± SEM was calculated and the data illustrated in figure form. If indicated, the data were analyzed using the Kruskal-Wallis ANOVA and post hoc Mann-Whitney U-Tests.
Comparative Data (ED50 or AD50, mg/kg s. Meperidine . HC1 8.37 Inactive ----4.6 (4. 59-15.27) (1.18-11.7) a Mice were ataxic at 3.0 and 10.0 mg/kg but there was no further increase in reaction time b ICR -Harlan-Sprague-Dawley Inc.
Calculation of Apparent pA2 . Using the tail-flick or PPQ assay, the apparent pA 2 and 95% confidence limits were calculated using Schild and constrained plots as described in Tallarida and Murray (Manual of Pharmacologic Calculations with Computer Programs, 2nd ed., Springer Verlag, NY., 1987) .
Briefly, mice were pretreated with vehicle or various doses of antagonist followed 10 min later by an injection of agonist. The mice were tested 30 min after receiving the antagonist. Dose-response lines for antinociception were plotted using at least 3 doses of each opioid agonist in the presence of vehicle or one of the selected doses of antagonist. ED5Os were estimated according to the method of Litchfield and Wilcoxon (J. Pharmacol. Exp. Ther., 96, 399, 1949) . Each dose ratio (x) was calculated by dividing the ED50 of the opioid in the presence of a given dose of antagonist by that of the agonist alone. Log (x-l ) was plotted against the negative logarithm of the molar dose of the antagonist. At least 3 logs (x-l) were plotted. The pA 2 values for the antagonists were calculated from the point of intersection of the regression line with the abscissa. See Table 3 for summary of results. 6.2 (6.1 -6.2)-1.7 6.5 (5.9 -7.0)-1.3
6.6 (6.2 -6.9)-0.9 7.3 (7.1 -7.6) 7.0 (6.8 -7.1)
7.2 (6.9 -7.5)
6.6 (6.3 -7.0) 6.2 (5.9 -7.3) -8.0 (7.7 -7.6) 7.6 (7.1 -8.3)
6.8 (6.1 -7.6) 6.7 (6.6 -6.8) 6.6 (5.9 -7.3) -a Negative logarithm of the molar concentrations of antagonist required to produce a two-fold shift of the agonist dose-response curve to the right. Competitive antagonism can be assumed when slope = -1. pA 2 provides a measure of the relative potency and affinity of the antagonist. When the slope differs significantly from unity, this may indicate non-equilibrium conditions, interactions with multireceptors, receptor sensitization, precoupling mechanisms, or multiple drug properties. With a constrained plot, the slope of the regression line is restricted to slope of -1.
Special Intracerebroventricular Tail-Flick and PPQ Assays. In order to develop an in-vivo agonist and antagonist model to correlate with the in-vitro binding data of the various opioid receptor types (mu, kappa and delta), we chose the mouse Tail-Flick and PPQ tests and a variety of routes of administration. The intracerebroventricular (i.c.v.) route was chosen to accommodate the fact that no delta agonist is available which is active by peripheral routes of administration. 
NIH 10589

Fig NIH 10589
Results of study in which single doses of NIH 10589 (Naltrindole) were substituted for morphine in morphine-dependent monkeys in withdrawal.
Comment: Naltrindole is a selective delta opioid antagonist in the PPQ test. Note however, that the drug also acts as a mu antagonist in the morphine-dependent monkey or perhaps reveals a delta component of withdrawal. c a 2 of 6 convulsed and died at 1 mg/kg and 1 of 6 convulsed but did not die at 1 mg/kg. b All convulsed and died at 10 and 30 mg/kg c All convulsed and died at 10 mg/kg and 4 of 8died at 3 mg/kg. Special: Naloxone vs NIH 10967 ED 80 in PPQ test = 0% antagonism.
MONKEY DATA (SDS)
Not tested.
Comment: The compound displayed potent antinociceptive effects. However, the drug also produced convulsions and was lethal. The profile of activity does not indicate opioid properties. Natrindole vs NIH 11011, 60 mg/kg, in PPQ Test: Antagonism = 23% at 1, 33% at 3, 11% at 10 and 0% at 30.
Attenuation of withdrawal signs at 16 mg/kg was accompanied by jaw sag and ataxia. These behavioral signs and salivation were also noted at the lower dose.
Drug supply was exhausted. Thus, a complete evaluation of NIH 11011 was precluded. Fig NIH 11011 -SDS. Results of study in which single doses of NIH 11011 were substituted for morphine in morphine-dependent monkeys in withdrawal.
Comment: The profile of activity does not suggest mu opioid-receptor interactions. At 4 and 16 mg/kg, some partial attenuation of withdrawal signs was observed (see figure) . The effect was not dose related. Jaw sag was noted in one monkey at the high dose. The drug acted promptly. Duration of action was 2 1/2 hr. Vehicle was 10% hydroxypropyl-β-cyclodextrin in water.
Fig NIH 11029-SDS. Results of study in which single doses of NIH 11029 were substituted for morphine in morphine-dependent monkeys in withdrawal.
Comment: The profile of activity does not indicate significant opioid effects. Vehicle was water aided by warming.
HO OH
NIH 11032 (-)-(1R,5R,9R)-2-(3-cis -Chloro-2-propenyl)-5,9-dimethyl-2'-
MONKEY DATA (SDS)
NIH 11032 did not substitute for morphine and may have exacerbated withdrawal. Because the vehicle controls showed fewer than the usual number of withdrawal signs, the exacerbation of withdrawal depicted in the figure may be exaggerated. The drug does produce some jaw sag and slowing in 1/3 at 1.25 mg/kg and jaw sag in 2/3, slowing in 2/3 and body sag in 1/3 monkeys at 5 mg/kg. Vehicle was 10% aqueous hydroxypropyl-β-cyclodextrin solution. NIH 11036 (+)-(1S,5S,9S)-5,9-Dimethyl-2'-methoxy -2-(2-propenyl)-6,7-benzomorphan Oxalate MOUSE DATA -ED50 OR AD50 (95 % C.L.) (mg/kg or % change) 1) TF -4% at 1, 5% at 10 and 0% at 30 2) TF vs. M -Inactive at 1, 10 and 30 3) PPQ -21.6 (12.7 -36.5) 4) HP -Inactive at 1, 10 and 30 5) TF -5% at 1 and 5, 25% and 31% at 10 and 12% at 30 c (Intravenously) c Tremors at 10 mg/kg and clonic convulsions, rapid respiration at 30. 1/6 Straub tail and 1/6 died at 30.
At doses of 4.5 and 18 mg/kg, NIH 11036 neither substituted for morphine nor exacerbated withdrawal (see figure) . At the low dose, overt behavioral signs designated as slowing (1/3) and ataxia (2/3) were noted. At the higher dose, slowing (2/3), ataxia (2/3), jaw sag 1/3), eyelid ptosis (2/3) and glassy eyes (1/3) were observed.
Fig NIH 11036-SDS. Results of study in which single doses of NIH 11036 were substituted for morphine in morphine-dependent monkeys in withdrawal.
Comment: The profile of activity in mice and monkeys is not indicative of mu -opioid agonist activity. However, the the drug has significant central nervous system depressant activity. 
At 2 mg/kg, NIH 11038 exacerbated withdrawal (see figure) . Onset was prompt and duration of action was at least 2 1/2 hr. Also noted, at 2 mg/kg was slowing in 3/4 and ataxia in 2/4 of the subjects. At 8 mg/kg, the signs slowing in 3/4, ataxia in 3/4, jaw sag in 2/4 and eyelid ptosis in 1/4 of the monkeys were observed during the first 90 min of the study. At doses of 1, 4 and 16 mg/kg, NIH 11041 neither substituted for morphine nor exacerbated withdrawal in morphine-dependent monkeys (see figure) . Jaw sag was observed at the lowest dose in one monkey, slowing and eyelid ptosis were noted in 1/3 at the next higher dose, and jaw sag, ataxia, slowing, vomiting and convulsions were noticed in one of two monkeys at the highest dose. Pentobarbital, 30 mg i.p., promptly terminated the convulsions. Drug supply was exhausted. Vehicle was 10% hydroxypropyl-β-cyclodextrin in water.
Fig NIH 11040 SDS. Results of study in which single doses of NIH 11040 were substituted for morphine in morphine-dependent monkeys in withdrawal.
Comment: The profile of activity exhibited by NIH 11040 does not portend remarkable mu -opioid properties. Antinociceptive activity in the PPQ test coupled with convulsions in the SDS study hint at delta-opioid activity. 
NIH 11042 did not substitute for morphine or exacerbate withdrawal (see figure) . Attenuation of withdrawal signs was probably associated with the side effects of the drug which were: ataxia in 3/4, slowing in 4/4, jaw sag in 1/4 at 1 mg/kg; body sag in 1/4 and eyelid ptosis in 1/4 at 4 mg/kg; and, ataxia in 2/2 and slowing in 2/2 at highest dose. 
Although NIH 11043 appeared to attenuate withdrawal signs in rhesus monkeys in a dose-related manner (see accompanying figure) , the reduction in signs was probably associated with the severe side effects of the drug. At the high dose, 4/4 were severely ataxic, 4/4 were slow, 3/4 had jaw sag, 2/4 had eyelid ptosis and 1/4 developed body sag. The drug acted promptly and its effects lasted for approximately 90 min. The behavioral signs exhibited by NIH 11044 suggested multiple opioid properties. The signs designated jaw sag, slowing, eyelid ptosis, vomiting and, especially salivation, suggested kappa-opioid agonist properties. Also observed, were the signs designated retching, vomiting, tremors, and rigid abdominal muscles accompanied by vocalization when palpated, indicative of mu -opioid receptor antagonist activity. It should be noted that vomiting is noted infrequently in abruptly withdrawn morphine-dependent monkeys. This sign is usually associated with precipitated withdrawal. These effects were dose-related, of rapid onset and were diminished after 90 min. At 1 mg/kg, the drug appeared to exacerbate withdrawal. At the highest dose (10 mg/kg), the results depicted in the accompanying figure suggest that this compound was attenuating withdrawal. However, this interpretation is probably not correct because all the monkeys receiving this dose refused to leave the pen to have their abdomens palpated during the 30-min check. Two would not leave the pen during the 60-min examination and 1 declined the 90-min check. The end result was a lower than normal cumulative withdrawal score. 
With NIH 11045 there is evidence for heterogeneous opioid subtype activity in the morphine-dependent monkey in abrupt withdrawal. This compound displayed a behavioral profile not unlike that of NIH 11044. The signs designated jaw sag, ataxia, slowing, eyelid ptosis, tremors and salivation were noted. The effects appeared doserelated. The drug acted promptly and the duration of action was 90 to 120 min. In addition, 3 monkeys refused to leave their pen during the 30-min abdominal muscles check; 2 would not leave their pen during the 60-min examination; and, 1 would not leave its pen until the 120-min interval. Comment: In the mouse, NIH 11045 displayed mu -and kappa-opioid receptor antagonist activity. Its potency as a mu -opioid receptor antagonist was very weak or approximately 1/100 that of the reference standard, naloxone. Potency as a kappa-opioid receptor antagonist was about equivalent to that of norbinaltorphimine (nBNI). However, onset of action was much faster (30 min) than that of nBNI (2 hr). The behavioral profile in the withdrawn morphine-dependent monkey suggested mu -antagonist and kappa agonist properties. NIH 11051 attenuated withdrawal signs (see figure) . However, severe dose-related CNS depressant properties were noted. Slowing, ataxia and salivation were seen. One monkey fell from its perch but was fully recovered after 90 min.
(R) (R)
Fig NIH 11051 SDS. Results of study in which single doses of NIH 11051 were substituted for morphine in morphine-dependent monkeys in withdrawal.
Comment: The mice and monkeys showed behavioral signs consistent with those produced by CNS depressants. Limited supplies precluded a full evaluation.
NIH 11052 (-)-(1R,5R,9R)-5,9-Dimethyl-2-(2-propenyl)-2'-propionoxy -6,7-benzomorphan.HCl a Drug was dissolved in 100% DMSO. When attempts were made to dilute this stock solution with water, particles formed and adhered to sides of container. Therefore, dilutions were made using 100% DMSO. Vehicle alone, 100% DMSO, produced 9% effect at 0.1 ml and 24% effect at 0.3 ml. . b Inactivity, eyelid ptosis, arched backs and large wheals at sites of injection.
Comment: This drug could not be reliably tested because of problems with solubility. Apparently DMSO, per se, accounts for the activity noted. a Drug was dissolved in 100% DMSO. When attempts were made to dilute this stock solution with water, particles formed and adhered to sides of container. Therefore dilutions were made using 100% DMSO. Vehicle alone, 100% DMSO, produced 11% effect at 0.1 ml and 12 to 86% effect at 0.3 ml. b Inactivity, eyelid ptosis and large wheals at sites of injection.
Comment: This drug could not be reliably tested because of problems with solubility. Apparently DMSO per se, accounts for the activity noted. 
Comment:
Although NIH 11083 is very potent mu -opioid receptor antagonist, its duration of action is not remarkable. Potency estimate is 10 times that of naloxone. 3) PPQ -18% at 1, 8% at 3, 0% and 70% at 10 (tested twice at 10) and 40% and 16% at 30 (tested twice at 30) a 4) HP -25% at 1, 13% at 10 and 0% at 30 a Vehicle was 10% hydroxypropyl-β-cyclodextrin in water.
Comment: NIH 11085 displays a rather erratic dose-response in the PPQ test. This drug probably lacks mu -opioid receptor activity in mice.
a Vehicle was 10% hydroxypropyl-β-cyclodextrin in water. 
